A Gutsy Combination: The Microbiome and Immuno-oncology
As science explores the effects of the microbiome on the immune system and its role in treating cancer, drug developers are investing substantially to capitalize on findings connecting the microbiome, immunology, and oncology.
For our latest white paper, Back Bay Life Science Advisors analyzed the activity of drug developers looking to harness microbial pathways to improve cancer treatment, the current drug pipeline, active clinical trials, and evolving regulatory and IP issues for the development of these technologies.
August 16, 2019 – Back Bay Senior Vice President Steve Gauldie spoke with the Boston Business Journal about new drug regulation:
The Boston Business Journal: Gene therapies to test FDA’s approach to regulating drugs after launch, experts say.
August 2, 2019 – Back Bay Senior Vice President Chris Leo spoke with the Boston Business Journal about the critical period ahead for Boston-based giant, Biogen.
Boston Business Journal: Biogen on the Brink: One of the pillars of the local life science industry faces a crisis
Senior leaders gather to share best practices and build real-world solutions
July 1, 2019 (CAMBRIDGE, MA) – The Massachusetts Biotechnology Council (MassBio®), launched an Academic-Industry Roundtable Series to create pathways for better collaboration and progress innovative technologies in the life sciences. The inaugural meeting, held in late June, brought together a new working group – comprised of senior leaders from leading academic institutions and industry– designed to define best practices and catalyze academic-industry collaboration.(more…)
Philadelphia, June 3-6, 2019 – Back Bay Life Science Advisors is at the BIO International Convention, the world’s largest biotechnology partnering event.
Back Bay strategy and banking experts are onsite, and our CEO, Jonathan P. Gertler, MD will again serve as on the panel of expert judges at BIO’s Start-Up Stadium, to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, and BIO attendees.
BIO International celebrates the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Known for top-notch business partnering, networking with 16,000 peers, and insight via hundreds of education sessions, BIO is on Back Bay’s annual roster of must-do conferences.
Will you be at BIO? Connect with us to meet onsite with one of our strategy or banking experts.
Back Bay Life Science Advisors is proud to have served as exclusive strategic and financial advisors to Centrexion Therapeutics in the licensing agreement of its non-opioid pain asset to Eli Lilly and Company (NYSE: LLY). Centrexion is due $47.5 million upfront with the potential to receive an additional $950 million in development and commercial milestones as well as royalties.
Lilly today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics, Inc. for their novel, small molecule somatostatin receptor type 4 (SSTR4) agonist, currently in Phase I clinical testing as a potential non-opioid treatment for chronic pain conditions.
After providing ongoing strategic support to Centrexion, Back Bay Life Science Advisors was pleased to take an exclusive advisory role in this global licensing agreement. We look forward to the continued success of Centrexion and Lilly in the development of non-opioid, non-addictive therapeutics for chronic pain.
Back Bay Vice President Peter Bak spoke with the GlobalData-Investigative News Team about lagging antibiotic sales.
“Flawed reimbursement dynamics are significantly hurting recent antibiotic sales, which are failing market projections, and similar repercussions are expected for upcoming launches, said experts. While discussions around implementing alternative payment models for these drugs are active, efforts to alleviate price pressures are unlikely to materialize soon,” according to BioPharm Insight.(more…)
Boston biotech financing and innovation flow are at all-time highs and “the fight over local talent is fueling scientific innovation and creating a financial boon for executives and employees,” according to the Boston Business Journal.
This month, Back Bay CEO, Jonathan P. Gertler, spoke with the Journal about the demand for life science executives in Greater Boston, and the value of a strong executive team in building a successful biotech company.
Back Bay CEO Jonathan P. Gertler, MD and Back Bay Senior Vice President, Stephan Gauldie,
Xconomy recently reported that Gossamer Bio will return to a conventional IPO approach: “With SEC Reopened, Gossamer Bio Turns Back from Alternative IPO Path.”
Back Bay managing director and M&A expert, Vasilios Kofitsas noted that “a company that decides to take the fixed-price route is likely very comfortable with its valuation—and with its disclosures to investors.
There’s certainly risk from a company perspective should you go this route and price successfully – and the SEC comes back and notices it has issues with lack of disclosures, for example.
. . . also, there is
Read about Gossamer Bio at Xconomy.com.
This month, Back Bay CEO, Jonathan P. Gertler, MD, spoke with the Boston Business Journal about the effects on Massachusetts businesses of the federal government’s ongoing partial shutdown. Along with far-reaching impact, here in the Baystate, the shutdown is halting or slowing many of the processes area businesses rely upon, “such as those handled by agencies like the Securities and Exchange Commission, the Internal Revenue Service or the Food and Drug Administration,” reports the BBJ.